Dermata Therapeutics Inc has a consensus price target of $9, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from Maxim Group, Brookline Capital, and Maxim Group on March 23, 2023, September 21, 2021, and September 14, 2021. With an average price target of $9 between Maxim Group, Brookline Capital, and Maxim Group, there's an implied 2712.50% upside for Dermata Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Dermata Therapeutics (NASDAQ: DRMA) was reported by Maxim Group on March 23, 2023. The analyst firm set a price target for $4.00 expecting DRMA to rise to within 12 months (a possible 1150.00% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Dermata Therapeutics (NASDAQ: DRMA) was provided by Maxim Group, and Dermata Therapeutics maintained their buy rating.
There is no last upgrade for Dermata Therapeutics.
There is no last downgrade for Dermata Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dermata Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dermata Therapeutics was filed on March 23, 2023 so you should expect the next rating to be made available sometime around March 23, 2024.
While ratings are subjective and will change, the latest Dermata Therapeutics (DRMA) rating was a maintained with a price target of $16.00 to $4.00. The current price Dermata Therapeutics (DRMA) is trading at is $0.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.